Received: from DB4PR02MB9358.eurprd02.prod.outlook.com (2603:10a6:10:3fd::14) by VI1PR02MB5024.eurprd02.prod.outlook.com with HTTPS; Thu, 30 Apr 2026 08:54:07 +0000 Received: from GV2PR02MB11921.eurprd02.prod.outlook.com (2603:10a6:150:351::5) by DB4PR02MB9358.eurprd02.prod.outlook.com (2603:10a6:10:3fd::14) with Microsoft SMTP Server (version=TLS1_2, cipher=TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384) id 15.20.9870.20; Thu, 30 Apr 2026 08:54:03 +0000 Received: from GV2PR02MB11921.eurprd02.prod.outlook.com ([fe80::9f24:8c81:10e8:7104]) by GV2PR02MB11921.eurprd02.prod.outlook.com ([fe80::9f24:8c81:10e8:7104%4]) with mapi id 15.20.9870.020; Thu, 30 Apr 2026 08:54:03 +0000 From: "Kristi Sarap - RA" To: Subject: Ravimaimeti vastus Date: Thu, 30 Apr 2026 11:54:03 +0300 Message-ID: MIME-Version: 1.0 Content-Type: multipart/alternative; boundary="----=_NextPart_000_0047_01DCE39D.97E4D800" X-Mailer: Microsoft Outlook 16.0 Thread-Index: AQGwquQ0CbX5db9WxWb+UQdea9mGgw== Authentication-Results: dkim=none (message not signed) header.d=none;dmarc=none action=none header.from=ravimiamet.ee; X-MS-Has-Attach: X-MS-TNEF-Correlator: X-MS-Exchange-Organization-Network-Message-Id: d124f692-471e-491f-945a-08dea6960766 X-MS-Exchange-Organization-AuthSource: GV2PR02MB11921.eurprd02.prod.outlook.com X-MS-Exchange-Organization-AuthAs: Internal X-MS-Exchange-Transport-EndToEndLatency: 00:00:03.8342356 X-MS-Exchange-Processed-By-BccFoldering: 15.20.9846.012 Content-Language: et x-ms-exchange-organization-originalclientipaddress: 45.156.32.33 x-ms-exchange-organization-originalserveripaddress: 2603:10a6:150:351::5 acceptlanguage: et-EE, en-US X-OlkEid: 000000004C30E2D3CD34B4428531CBEB8A7CAB89070034AD76187591974DBF6C4F76951C873A0100020000000000B04CDEF8D3227A448511457FBBCE9C8700000000088E000080903A8C42A17546B876D8CF1C4FE4FF X-MS-Exchange-Organization-SCL: 1 X-MS-Exchange-Organization-MessageDirectionality: Originating X-MS-Exchange-Organization-AuthMechanism: 04 x-ms-traffictypediagnostic: GV2PR02MB11921:EE_|DB4PR02MB9358:EE_|VI1PR02MB5024:EE_ X-MS-Office365-Filtering-Correlation-Id: d124f692-471e-491f-945a-08dea6960766 X-MS-Exchange-AtpMessageProperties: SA X-MS-Exchange-Transport-CrossTenantHeadersStamped: DB4PR02MB9358 X-CodeTwoProcessed: true X-MS-Exchange-Organization-ExpirationStartTime: 30 Apr 2026 08:54:04.0184 (UTC) X-MS-Exchange-Organization-ExpirationStartTimeReason: OriginalSubmit X-MS-Exchange-Organization-ExpirationInterval: 1:00:00:00.0000000 X-MS-Exchange-Organization-ExpirationIntervalReason: OriginalSubmit X-MS-Exchange-Organization-Recipient-P2-Type: Bcc X-MS-PublicTrafficType: Email X-Microsoft-Antispam: BCL:0;ARA:13230040|31052699007|39142699007|366016|13003099007|18002099003|56012099003|8096899003|55112099003|41050700001; X-Forefront-Antispam-Report: CIP:255.255.255.255;CTRY:;LANG:et;SCL:1;SRV:;IPV:NLI;SFV:NSPM;H:GV2PR02MB11921.eurprd02.prod.outlook.com;PTR:;CAT:NONE;SFS:(13230040)(31052699007)(39142699007)(366016)(13003099007)(18002099003)(56012099003)(8096899003)(55112099003)(41050700001);DIR:INT; X-MS-Exchange-CrossTenant-OriginalArrivalTime: 30 Apr 2026 08:54:03.2150 (UTC) X-MS-Exchange-CrossTenant-Network-Message-Id: d124f692-471e-491f-945a-08dea6960766 X-MS-Exchange-CrossTenant-Id: 8fe098d2-428d-4bd4-9803-7195fe96f0e2 X-MS-Exchange-CrossTenant-AuthAs: Internal X-MS-Exchange-CrossTenant-AuthSource: GV2PR02MB11921.eurprd02.prod.outlook.com X-MS-Exchange-CrossTenant-FromEntityHeader: Hosted X-MS-Exchange-ExternalInOutlookResult: NotEnabled X-Microsoft-Antispam-Mailbox-Delivery: ucf:0;jmr:0;auth:0;dest:I;ENG:(910005)(944506478)(944626604)(920097)(425001)(930201)(20251009189)(140003); X-Microsoft-Antispam-Message-Info: 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 msip_labels: MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_Enabled=True;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_SiteId=8fe098d2-428d-4bd4-9803-7195fe96f0e2;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_SetDate=2026-04-30T08:54:02.519Z;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_Name=All Employees (unrestricted);MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_ContentBits=1;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_Method=Standard; X-LD-Processed: 8fe098d2-428d-4bd4-9803-7195fe96f0e2,ExtAddr X-MS-Exchange-MessageSentRepresentingType: 1 X-MS-Exchange-Organization-ModifySensitivityLabel: 00000000-0000-0000-0000-000000000000;defa4170-0d19-0005-0004-bc88714345d2 x-codetwo-clientsignature-inserted: true X-MS-Exchange-CrossTenant-MailboxType: HOSTED X-MS-Exchange-CrossTenant-UserPrincipalName: kKkH+QBK1yS4d7ie3ruvrbPe140gl5n16SAHAdXHaJ0/UT8ECDgkjML0ppCmAmMCyTdi7xSllCWt+v5XqiL+ipvjWwdozho8AF4YuxfaHoN65YouI6GYBz+WPSxc+Cgc This is a multipart message in MIME format. ------=_NextPart_000_0047_01DCE39D.97E4D800 Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: 8bit Tere, Sarah! Ravimiameti poolt vastab järelevalveosakonna spetsialist Evelin Saar. "Tareen (Taren) kuulub Eestis narkootiliste ja psühhotroopsete ainete nimekirja ning selle müümine eraisikute poolt on keelatud. Nõukogude ajal kasutati seda mürkainete vastase esmaabivahendina. Tegemist on tugeva toimega ainete seguga, millel on ka narkootiline mõju. Tareen võib põhjustada hallutsinatsioone ning tõsiseid närvisüsteemi kahjustusi. Ravimiameti hinnangul võivad aegunud, eriti üle 30 aasta vanused ained olla äärmiselt toksilised ning nende manustamine võib kaasa tuua raskeid tervisekahjustusi. Sellised ained tuleks viivitamata viia ohtlike jäätmete kogumispunkti." Kristi Sarap kommunikatsiooninõunik Ravimiamet Ravimiamet 737 4140 www.ravimiamet.ee Selles e-kirjas sisalduv teave (kaasa arvatud manused) on mõeldud ametialaseks kasutamiseks ning seda võivad kasutada vaid e-kirja adressaadid. E-kirjas sisalduvat teavet ei tohi ilma saatja selgelt väljendatud loata edasi saata ega mis tahes viisil kolmandatele isikutele avaldada. Juhul, kui Te olete saanud käesoleva e-kirja eksituse tõttu, teavitage sellest koheselt saatjat ning kustutage e-kiri. This e-mail and any attachments transmitted may contain confidential and privileged information. If you are not the intended recipient, please notify the sender immediately by returning the e-mail and permanently deleting what you have received. Any dissemination or use of this information by a third person without permission is prohibited and may be illegal. ------=_NextPart_000_0047_01DCE39D.97E4D800 Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable
Tere, Sarah!

Ravimiameti poolt vastab j=C3=A4relevalveosakonna spetsialist Evelin = Saar.

"Tareen (Taren) kuulub Eestis narkootiliste ja ps=C3=BChhotroopsete = ainete nimekirja ning selle m=C3=BC=C3=BCmine eraisikute poolt on = keelatud.
N=C3=B5ukogude ajal kasutati seda m=C3=BCrkainete vastase = esmaabivahendina. Tegemist on tugeva toimega ainete seguga, millel on ka = narkootiline m=C3=B5ju. Tareen v=C3=B5ib p=C3=B5hjustada = hallutsinatsioone ning t=C3=B5siseid n=C3=A4rvis=C3=BCsteemi = kahjustusi.
Ravimiameti hinnangul v=C3=B5ivad aegunud, eriti =C3=BCle 30 aasta = vanused ained olla =C3=A4=C3=A4rmiselt toksilised ning nende manustamine = v=C3=B5ib kaasa tuua raskeid tervisekahjustusi.
Sellised ained tuleks viivitamata viia ohtlike j=C3=A4=C3=A4tmete = kogumispunkti."


Kristi Sarap

kommunikatsioonin=C3=B5unik

Ravimiamet


Ravimiamet

737 4140

www.ravimiamet.ee


Selles e-kirjas sisalduv teave (kaasa arvatud manused) on = m=C3=B5eldud ametialaseks kasutamiseks ning seda v=C3=B5ivad kasutada = vaid e-kirja adressaadid. E-kirjas sisalduvat teavet ei tohi ilma saatja = selgelt v=C3=A4ljendatud loata edasi saata ega mis tahes viisil = kolmandatele isikutele avaldada. Juhul, kui Te olete saanud = k=C3=A4esoleva e-kirja eksituse t=C3=B5ttu, teavitage sellest koheselt = saatjat ning kustutage e-kiri. 
This e-mail and any attachments transmitted may = contain confidential and privileged information. If you are not the = intended recipient, please notify the sender immediately by = returning the e-mail and permanently deleting what you have = received. Any dissemination or use of this information by a third person without permission is = prohibited and may be illegal. 

------=_NextPart_000_0047_01DCE39D.97E4D800--